The bill amends Minnesota Statutes 2022, section 256.01, by adding a new subdivision focused on the treatment of sickle cell disease. It mandates the commissioner of human services to conduct an annual review of medications and treatments available for sickle cell disease, specifically for medical assistance enrollees. The review aims to assess whether the current offerings are sufficient to meet the needs of these enrollees and to determine if additional treatments or services should be sought.

Furthermore, the bill requires the commissioner to solicit input from the public, particularly from individuals or groups knowledgeable about sickle cell disease treatment, during the review process. The commissioner is also tasked with submitting an annual report detailing the findings and recommendations to the relevant legislative committees by January 15 each year, starting in 2025. Notably, the reporting requirement established by this subdivision does not expire, ensuring ongoing oversight and evaluation of sickle cell disease treatments.

Statutes affected:
Introduction: 256.01